Drug Trial Radar · NCT00599196
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Oct 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
381
Actual
Start
Aug 2002
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Jan 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
Conditions
- Early Stage Parkinson's Disease
Interventions
RotigotineDrug
Rotigotine trans-dermal patches, once daily: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours); Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours. After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With at Least One Adverse Event During This Open-label Extension StudyTime frame: six years
Locations
63 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Concord, Australia
Site not named
Darlinghurst, Australia
Site not named
East Gosford, Australia
Site not named
Westmead, Australia
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Brussels, Belgium
Site not named
Hoboken, Belgium
Site not named
Zagreb, Croatia
Site not named
Brno, Czechia
Site not named
Ostrava, Czechia
Site not named
Pilsen, Czechia
Site not named
Espoo, Finland
Site not named
Kuopio, Finland
Site not named
Lappeenranta, Finland
Site not named
Oulu, Finland
Site not named
Pori, Finland
Site not named
Aix-en-Provence, France
Site not named
Caen, France
Site not named
Toulouse, France
Site not named
Aachen, Germany
Site not named
Dresden, Germany
Site not named
Kiel, Germany
Site not named
Marburg, Germany
Site not named
Budapest, Hungary
Site not named
Miskolc, Hungary
Site not named
Pécs, Hungary
Site not named
Hadera, Israel
Site not named
Petah Tikva, Israel
Site not named
Tel Aviv, Israel
Site not named
Milan, Italy
Site not named
Padova, Italy
Site not named
Pozzilli, Italy
Site not named
Breda, Netherlands
Site not named
Geldrop, Netherlands
Site not named
Auckland, New Zealand
Site not named
Christchurch, New Zealand
Site not named
North Shore, New Zealand
Site not named
Wellington, New Zealand
Site not named
Stavanger, Norway
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.